FGFR3-TACC3 was enriched in acquired resistance to epidermal growth factor receptor-targeted therapy in patients with NSCLC [[38], [39], [40]], suggesting that FGFR3-TACC3 fusion is a recurrent resistance mechanism in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.